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Abstract
IMPORTANCE In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk
stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%,
respectively, with adjuvant fluorouracil and oxaliplatin–based chemotherapy; however, the trial did
not demonstrate a disease-free survival (DFS) benefit of adding bevacizumab to oxaliplatin-based
chemotherapy in stage III CC and suggested a detrimental effect on OS. The Long-term Survival
AVANT (S-AVANT) study was designed to collect extended follow-up for patients in the AVANT trial.
OBJECTIVE To explore the efficacy of adjuvant bevacizumab combined with oxaliplatin-based
chemotherapy in patients with high-risk, stage II CC.
DESIGN, SETTING, AND PARTICIPANTS This prespecified secondary end point analysis of the
AVANT and S-AVANT studies included 573 patients with curatively resected high-risk stage II CC and
at least 1 of the following criteria: stage T4, bowel obstruction or perforation, blood and/or lymphatic
vascular invasion and/or perineural invasion, age younger than 50 years, or fewer than 12 nodes
analyzed. The AVANT study was a multicenter randomized stage 3 clinical trial. Data were collected
from December 2004 to February 2019, and data for this study were analyzed from March to
September 2019.
INTERVENTION Patients were randomly assigned to receive 5-fluorouracil, leucovorin, and
oxaliplatin (FOLFOX4), FOLFOX4 with bevacizumab, or capecitabine and oxaliplatin (XELOX) with
bevacizumab.
MAIN OUTCOMES AND MEASURES The primary end points of this secondary analysis were DFS
and OS in patients with high-risk stage II CC.
RESULTS The AVANT study included 3451 patients, of whom 573 (16.6%) had high-risk stage II CC
(192 [33.5%] randomized to FOLFOX4 group; 194 [33.9%] randomized to FOLFOX4 with
bevacizumab group; 187 [32.6%] randomized to XELOX with bevacizumab group). With a median
(interquartile range) age of 57.0 (47.2-65.7) years, the study population comprised 325 men (56.7%)
and 248 women (43.3%). After a median (interquartile range) follow-up of 6.9 (6.1-11.3) years, the
3-year DFS and 5-year OS rates were 88.2% (95% CI, 83.7%-93.0%) and 89.7% (95% CI,
85.4%-94.2%) in the FOLFOX4 group, 86.6% (95% CI, 81.8%-91.6%) and 89.7% (95% CI, 85.4%-
94.2%) in the FOLFOX4 with bevacizumab group, and 86.7% (95% CI, 81.8%-91.8%) and 93.2%
(95% CI, 89.6%-97.0%) in the XELOX with bevacizumab group, respectively. The DFS hazard ratio
was 0.94 (95% CI, 0.59-1.48; P = .78) for FOLFOX4 with bevacizumab vs FOLFOX4 and 1.07 (95% CI,
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Key Points
Question What was the efficacy of
adjuvant bevacizumab on disease-free
and overall survival among patients with
curatively resected high-risk stage II
colon cancer?
Findings In this secondary analysis of
573 patients with high-risk stage II colon
cancer enrolled in the AVANT trial, the
addition of bevacizumab to oxaliplatin-
based chemotherapy did not prolong
disease-free survival or overall survival.
The 5-year survival rates in patients with
high-risk stage II colon cancer in this
study were 89.7% in the FOLFOX4
control group and in the FOLFOX4 with
bevacizumab group and 93.2% in the
XELOX with bevacizumab group.
Meaning The findings of this study
suggest that adding bevacizumab to
oxaliplatin-based chemotherapy was
not associated with longer DFS or OS in
patients with high-risk stage II colon
cancer and that the definition of high-
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Abstract (continued)
0.69-1.67; P = .76) for XELOX with bevacizumab vs FOLFOX4. The OS hazard ratio was 0.92 (95% CI,
0.55-1.55; P = .76) for FOLFOX4 with bevacizumab vs FOLFOX4 and 0.85 (95% CI, 0.50-1.44;
P = .55) for XELOX with bevacizumab vs FOLFOX4.
CONCLUSIONS AND RELEVANCE In this secondary analysis of data from the AVANT trial, adding
bevacizumab to oxaliplatin-based chemotherapy was not associated with longer DFS or OS in
patients with high-risk stage II CC. The findings suggest that the definition of high-risk stage II CC
needs to be revisited.
TRIAL REGISTRATION ClinicalTrial.gov Identifiers: AVANT (NCT00112918); S-AVANT (NCT02228668)
JAMA Network Open. 2020;3(10):e2020425. doi:10.1001/jamanetworkopen.2020.20425
Introduction
Colorectal cancer (CRC) is the fourth most common cancer in the world and the fifth leading cause of
death.1 Nearly 25% of colon cancers (CCs) are diagnosed with stage II disease in western countries.2
In the pivotal Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant
Treatment of Colon Cancer (MOSAIC) trial, which assessed the addition of oxaliplatin to fluorouracil,
patients with high-risk stage II CC had 5-year and 10-year overall survival (OS) rates of 88% and 75%,
respectively, with adjuvant folinic acid, fluorouracil, oxaliplatin (FOLFOX) chemotherapy.3,4 However,
the use of adjuvant therapy for patients with stage II CC remains controversial.
The survival benefit of 6-month adjuvant therapy with bolus 5-fluorouracil/leucovorin
(5-FU/LV) in patients with resected, node-positive CC (stage III) was established in the 1990s.5-7 It
was later superseded in trials by infusional 5-FU/LV regimens, which showed an improved safety
profile.8 The efficacy of 5-FU/LV in adjuvant therapy for stage II CC was established by the Quick and
Simple and Reliable (QUASAR) study.9 In the population with stage II disease, this study showed that
adjuvant chemotherapy decreased the relative risk of recurrence by 29% (hazard ratio [HR], 0.71;
95% CI, 0.54-0.92), but there was no difference in OS (HR, 0.83; 95% CI, 0.65-1.07). However, the
absolute benefit of adjuvant fluoropyrimidine was only 2.9%, leading to an absence of therapeutic
consensus.9 Further changes to adjuvant treatment have since been made by the addition of
oxaliplatin to fluoropyrimidines (5-FU/LV or capecitabine), reducing the relative risk of recurrence by
20% to 23% in patients with stage III CC.3,10,11 In the MOSAIC study, oxaliplatin added to 5-FU/LV had
some activity in patients with high-risk stage II CC. The 5-year disease-free survival (DFS) rate for
these patients was 82.3% (vs 74.6% for those receiving only 5-FU/LV; HR, 0.72; 95% CI, 0.50-1.02).
However, OS was not increased.12 Considering these results, adjuvant treatment for stage II CC is
discussed according to tumor-related prognostic factors and should be balanced with patient’s
comorbidity and life expectancy.
Vascular endothelial growth factor inhibition with bevacizumab, a humanized anti–vascular
endothelial growth factor monoclonal antibody, has a direct antivascular effect in human tumors,
improving OS when given with chemotherapy in patients with metastatic CRC.13,14 The Bevacizumab-
Avastin Adjuvant (AVANT) trial, a 3-group multinational phase 3 study, failed to demonstrate the
superiority of bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) or
capecitabine and oxaliplatin (XELOX) compared with FOLFOX4 alone in terms of DFS in patients who
had undergone surgery with curative intent for stage III CC.15
The National Surgical Adjuvant Breast and Bowel Project C-08 phase 3 trial also investigated the
efficacy of bevacizumab plus adjuvant oxaliplatin-based chemotherapy in US patients with stage II
or III CC.16 Similarly, adding bevacizumab did not increase DFS. In that study,16 the effect of
bevacizumab treatment did not vary by stage. QUASAR2 evaluated adjuvant capecitabine plus
bevacizumab vs capecitabine alone in patients with high-risk stage II or stage III CRC. The addition of
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bevacizumab to capecitabine yielded no DFS benefit (HR, 1.06; 95% CI, 0.89-1.25).17 In the present
study, we report the updated results of bevacizumab as adjuvant therapy combined with oxaliplatin-
based chemotherapy in the exploratory cohort of patients with high-risk stage II CC, who were
included in the AVANT trial.
Methods
Study Design and Treatment
The AVANT trial was a prospective, multicenter, randomized, parallel, 3-group phase 3 trial
conducted from December 2004 to June 2007. The primary objective was to evaluate the addition
of bevacizumab to a standard oxaliplatin-based chemotherapy regimen in patients with stage III CC.
Patients with high-risk stage II CC were also eligible for secondary objectives. A total of 2867 patients
with stage III CC and 573 patients with stage II were randomized. Full details of the trial design were
published in 2012.15
Eligible patients were aged 18 years or older and had an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1 with histologically confirmed stage III or high-risk stage II CC
(defined by the American Joint Cancer Committee/Union for International Cancer Control). Patients
with stage II CC were considered high-risk if they fulfilled at least 1 of the following criteria: younger
than 50 years, stage T4, perforation or obstruction, fewer than 12 lymph nodes examined, or vascular
(ie, blood and lymphatic vessels) or perineural invasion. Curative surgery was performed 4 to 8
weeks before randomization.
Key exclusion criteria included remaining tumor, carcinoembryonic antigen level greater than 1.5
times the upper reference limit after surgery, previous antiangiogenic treatment, major surgical
procedure, open biopsy, significant traumatic injury fewer than 28 days before study treatment start,
and abnormal hematological, liver, or renal function.
The study was done in accordance with the Declaration of Helsinki,18 and the protocol
(Supplement 1) was approved by the ethics review committees or boards of the institutions involved
in this multinational study. Patients provided written informed consent. This study follows the
Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.
Randomization was performed after surgery using a centralized interactive computerized
system and stratified according to geographic region (n = 8) and disease stage. The study had an open-
label design.
Patients were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment options: FOLFOX4 for 24
weeks followed by observation for 24 weeks; FOLFOX4 with bevacizumab for 24 weeks followed by
bevacizumab monotherapy for 24 weeks, or XELOX with bevacizumab for 24 weeks followed by
bevacizumab monotherapy for 24 weeks. FOLFOX4 and XELOX were given as described
previously.3,10 Bevacizumab was administered as a 30-minute to 90-minute intravenous infusion on
day 1 before oxaliplatin (5 mg/kg every 2 weeks for FOLFOX4; 7.5 mg/kg every 3 weeks for XELOX).
Bevacizumab monotherapy was given at 7.5 mg/kg every 3 weeks.
Study End Points
The primary end point of the AVANT study was the superiority of bevacizumab with FOLFOX4 or
XELOX vs FOLFOX4 alone in terms of DFS in patients with stage III CC only. DFS was defined as the
time between randomization and recurrence, new occurrence of CRC, or death from any cause,
whichever occurred first. Patients who were event free at the clinical cutoff date were censored at
the last date at which they were known to be disease free. Recurrences and new occurrences were
based on an investigator tumor assessment, prescheduled every 6 months for 4 years following
randomization and scheduled annually thereafter. OS was defined as the time from randomization to
death. Patients who were still alive at the clinical cutoff date were censored at the date at which they
were last confirmed to be alive. Survival status was assessed every 6 months for the first 4 years
after randomization and annually thereafter. AVANT was an event and/or time-driven trial. The study
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continued until 36 months after the last patient was randomized, and results were mature for
analysis in 2010 for the study primary objective.
Adverse events were monitored starting 28 days after the last dose of study treatment and/or
the end of the observation phase and were graded according to National Cancer Institute Common
Toxicity Criteria for Adverse Events version 3.0. Safety was previously reported in the pooled
population of patients with stage II and stage III CC in the AVANT trial.15
Follow-up and Update
Follow-up was initially done by the sponsor Roche with a data lock on June 30, 2010, and a median
(range) follow-up of 48 (0-66) months. At that time, DFS but not OS was mature. Given the negative
results, Roche decided to close the trial. Consequently, following the investigators’ wish to obtain
mature survival data, the database was transferred to Gercor in 2012. The S-AVANT study was
designed to obtain the ultimate DFS and OS results with extended follow-up of patients previously
randomized in the AVANT trial and to provide estimates of long-term effects of bevacizumab added
to adjuvant chemotherapy in patients with stage II and stage III CC. Further analyses were performed
using updated individual patient data and focusing on DFS, OS, comorbidities observed during the
follow-up period, and reasons of deaths. Adverse events of special interest to bevacizumab and their
related serious adverse events were also collected. Long-term survival results in patients with stage
III CC were published previously.19 We report here the survival results of patients with high-risk stage
II CC.
Statistical Analysis
All patients with high-risk stage II CC who were randomized in the AVANT study were eligible for
exploratory analyses. DFS and OS were the primary end points of this prespecified secondary
analysis. Continuous and categorical variables were described using the median value with
interquartile range (IQR) and frequency with percentage, respectively. DFS and OS were estimated
using the Kaplan-Meier method, and the log-rank test was used to assess for treatment differences
overall. Follow-up was calculated using the reverse Kaplan-Meier estimation. Cox proportional
hazard models were performed to estimate the association of factors with DFS and OS by means of
HRs and 95% CIs. To assess the association between DFS and OS and the baseline parameters,
univariate Cox analyses were first carried out. Factors with P < .10 were then added to the final
multivariate Cox model, after consideration of collinearity among variables. The proportional hazard
assumption was checked using statistical tests and graphical diagnostics based on the scaled
Schoenfeld residuals. Treatment group associations (FOLFOX4 with bevacizumab vs FOLFOX4
alone, and XELOX with bevacizumab vs FOLFOX4 alone) with DFS and OS were assessed using
subgroup analyses, and results were summarized in forest plots. An interaction term in each
subgroup was obtained by considering the subgroup, the treatment group, and their interaction in a
Cox model. An exploratory analysis of OS according to the number of stage II high-risk factors was
performed. Considering that patients with high-risk stage II CC were recruited for exploratory
analyses and that their total number was restricted to approximately 16% of all patients, no formal
statistical hypotheses were formulated for this prespecified study analysis. P values are shown for
exploratory purposes and were not adjusted for multiple testing. All tests were 2-sided. All analyses




The AVANT study included 3451 patients, of whom 573 (16.6%) had stage II CC (192 [33.5%] in
FOLFOX4 group; 194 [33.9%] in FOLFOX4 with bevacizumab group; 187 [32.6%] in XELOX with
bevacizumab group) (Figure 1). With a median (IQR) age of 57.0 (47.2-65.7) years, the study
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population comprised 325 men (56.7%) and 248 women (43.3%). Patient characteristics and high-
risk stage II CC criteria are presented in Table 1 and eFigure 1 in Supplement 2. The most frequent
high-risk stage II criterion was fewer than 12 examined lymph nodes (243 patients [42.4%]). Of note,
318 patients (55.5%) had a single high-risk stage II criterion, and 255 patients (44.5%) had more than
1. When data were locked for analysis on February 15, 2019, the median (IQR) follow-up for the whole
population of high-risk stage II CC was 6.9 (6.1-11.3) years, with 6.9 (6.1-11.3) years in the FOLFOX4
group, 6.8 (6.2-11.3) years in the FOLFOX4 with bevacizumab group, and 6.9 (6.1-11.5) years in the
XELOX with bevacizumab group. Of 511 patients (89.2%) with high-risk stage II CC who were still alive
after the AVANT study, 217 (42.5%) had an updated median (IQR) follow-up of 11.6 (10.8-
12.6) years.
Survival Results
DFS was observed in 38 patients (19.8%) in the FOLFOX4 group, 36 (18.6%) in the FOLFOX4 with
bevacizumab group, and 40 (21.4%) in the XELOX with bevacizumab group. The 3-year DFS rate was
88.2% (95% CI, 83.7%-93.0%) in the FOLFOX4 group, 86.6% (95% CI, 81.8%-91.6%) in the
FOLFOX4 with bevacizumab group, and 86.7% (95% CI, 81.8%-91.8%) in the XELOX with
bevacizumab group (Figure 2A). The DFS HR was 0.94 (95% CI, 0.59-1.48; P = .78) for FOLFOX4
with bevacizumab vs FOLFOX4 alone and 1.07 (95% CI, 0.69-1.67; P = .76) for XELOX with
bevacizumab vs FOLFOX4 alone.
The 5-year OS rate was 89.7% (95% CI, 85.4%-94.2%) in the FOLFOX4 group, 89.7% (95% CI,
85.4%-94.2%) in the FOLFOX4 with bevacizumab group, and 93.2% (95% CI, 89.6%-97.0%) in the
XELOX with bevacizumab group (Figure 2B). The OS HR was 0.92 (95% CI, 0.55-1.55; P = .76) for
FOLFOX4 with bevacizumab vs FOLFOX4 alone and 0.85 (95% CI, 0.50-1.44; P = .55) for XELOX
with bevacizumab vs FOLFOX4 alone.
Forest plots for main prognostic factors of DFS and OS for the FOLFOX4 with bevacizumab
group and the XELOX with bevacizumab group vs the FOLFOX4 group are presented in eFigure 2 in
Supplement 2. There was no benefit of bevacizumab when added to FOLFOX4 in patients with right
CC in terms of DFS (HR = 0.50; 95% CI, 0.22-1.18) and OS (HR = 0.37; 95% CI, 0.13-1.02).
High-Risk Stage II Classification
Among the 318 patients (55.5%) classified as having high-risk stage II CC based on a single factor,
being younger than 50 years was observed in 62 (10.8%); vascular or perineural invasion, 51 (8.9%);
Figure 1. Flowchart of Participants in Bevacizumab-Avastin Adjuvant (AVANT) and Long-term Survival
Bevacizumab-Avastin Adjuvant (S-AVANT) Studies
573 Randomly assigned patients with
stage II disease in the AVANT study 
217 Patients with updated follow-up
573 Patients included in S-AVANT
intention-to-treat population
573 Randomly assigned patients with
stage II disease in the S-AVANT study 
356 Patients without updated follow-up
62 Died during the AVANT study
294 Received care at centers that
refused to enroll in S-AVANT
356 Patients included 
121 With FOLFOX4
126 With FOLFOX4 + bevacizumab
109 With XELOX + bevacizumab
217 Patients included 
71 With FOLFOX4
68 With FOLFOX4 + bevacizumab
78 With XELOX + bevacizumab
FOLFOX4 indicates 5-fluorouracil, leucovorin, and
oxaliplatin; and XELOX, capecitabine and oxaliplatin.
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stage T4, 67 (11.7%); perforation or obstruction, 38 (6.6%); and fewer than 12 examined lymph nodes
in 100 (17.5%). These patients’ OS curves showed that those who were younger than 50 years or who
presented with a vascular or perineural invasion had better survival than those with other high-risk
factors (Figure 3A). However, the difference was significant only for having fewer than 12 lymph
nodes examined (Table 2). Consequently, we defined age and vascular or perineural invasion as
favorable high-risk factors and the other high-risk factors (ie, <12 examined lymph nodes, stage T4,
and perforation or bowel obstruction) as unfavorable high-risk factors. Comparison of OS for
favorable high-risk factors vs a single unfavorable factor and 2 or more high-risk factors was also
significant (Figure 3B and Table 2).
Prognostic Factors
For DFS in univariate analysis, stage T4 vs T3, ECOG performance score 1 vs 0, fewer than 12 vs at
least 12 examined nodes, and age 50 years or older vs younger than 50 years were prognostic factors














Men 325 (56.7) 124 (64.6) 99 (51.0) 102 (54.5)
Women 248 (43.3) 68 (35.4) 95 (49.0) 85 (45.4)
Age, ya
Median (IQR) 57.0 (47.2-65.7) 57.2 (48.2-66.9) 57.1 (46.0-66.2) 56.1 (47.4-64.3)
<50 191 (33.3) 62 (32.3) 70 (36.1) 59 (31.5)
≥50 382 (66.7) 130 (67.7) 124 (63.9) 128 (68.4)
Primary tumor
Left or rectum 343 (61.9) 116 (62.03) 120 (64.5) 107 (59.1)
Right 211 (38.1) 71 (37.97) 66 (35.5) 74 (40.9)
Missing, No. 19 5 8 6
Differentiation
Poor 67 (12.2) 22 (12.1) 22 (11.7) 23 (12.8)
Moderate 374 (68.0) 121 (66.5) 132 (70.2) 121 (67.2)
Good 109 (19.8) 39 (21.4) 34 (18.1) 36 (20.0)
Missing, No. 23 10 6 7
ECOG performance status
0 464 (82.1) 161 (84.7) 160 (82.9) 143 (78.6)
1 101 (17.9) 29 (15.3) 33 (17.1) 39 (21.4)
Missing, No. 8 2 1 5
T stagea
3 362 (63.2) 124 (64.6) 119 (61.3) 119 (63.6)
4 211 (36.8) 68 (35.4) 75 (38.7) 68 (36.4)
Perforation or
obstructiona
No 428 (74.7) 145 (75.5) 139 (71.6) 144 (77.0)
Yes 145 (25.3) 47 (24.5) 55 (28.3) 43 (23.0)
Vascular or perineural
invasiona
No 456 (79.6) 152 (79.2) 157 (80.9) 147 (78.6)
Yes 117 (20.4) 40 (20.9) 37 (19.1) 40 (21.4)
Examined nodes
Median (IQR) 14 (8-21) 13 (7-20) 13 (9-21) 14 (7-21)
<12 243 (42.6) 82 (42.7) 83 (43.0) 78 (41.9)
≥12 328 (57.4) 110 (57.3) 110 (57.0) 108 (58.1)
Missing, No. 2 0 1 1
Abbreviations: ECOG, Eastern Cooperative Oncology
Group; IQR, interquartile range.
a No data were missing.
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(eTable 1 in Supplement 2). In multivariate analysis, stage T4 vs T3 and fewer than 12 vs at least 12
examined nodes remained prognostic (eTable 2 in Supplement 2).
For OS in univariate analysis, stage T4 vs T3, fewer than 12 vs at least 12 examined nodes, and
age 50 years or older vs younger than 50 were prognostic factors (eTable 1 in Supplement 2). In
multivariate analysis, stage T4 vs T3, fewer than 12 vs at least 12 examined nodes, and age 50 years
or older vs younger than 50 years remained prognostic (eTable 2 in Supplement 2).
Late Toxic Effects and Cause of Death
Early safety data of high-risk stage II and stage III CC were previously reported.15 With a total of 84
deaths, CC-related deaths occurred in 55 patients (65.5%) (18 of 30 [60.0%] in FOLFOX4 group; 19
of 28 [67.9%] in FOLFOX4 with bevacizumab group; 18 of 26 [69.2%] in XELOX with bevacizumab
group). Deaths related to cardiomyopathy, congestive heart failure, cardiac ischemia, pulmonary
embolism, stroke, intracranial hemorrhage, and sudden deaths were reported in 5 patients (16.7%)
in the FOLFOX4 group, 6 patients (21.4%) in the FOLFOX4 with bevacizumab group, and in 1 patient
(3.8%) in the XELOX with bevacizumab group. Other noncancer deaths or unknown causes of death
occurred in 7 patients (23.3%) in the FOLFOX4 group, 3 patients (10.7%) in the FOLFOX4 with
bevacizumab group, and 7 patients (26.9%) in the XELOX with bevacizumab group.
Figure 2. Disease-Free Survival and Overall Survival, According to Treatment Group, in 318 Patients













































































































































Global log-rank P =.84
FOLFOX4 indicates 5-fluorouracil, leucovorin, and
oxaliplatin; XELOX, capecitabine and oxaliplatin.
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Discussion
In this study, the 3-year DFS rates in patients with high-risk stage II CC were 88.2% in the FOLFOX4
group, 86.6% in the FOLFOX4 with bevacizumab group, and 86.7% in the XELOX with bevacizumab
Figure 3. Overall Survival According to High-Risk Stage II Criteria and to Favorable, Single Unfavorable,
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Vascular or perineural invasion
Favorable high-risk factors
Single unfavorable high-risk factor
Multiple high-risk factors Favorable high-risk factors included being younger
than 50 years and/or having vascular or perineural
invasion. Single unfavorable high-risk factors were
having fewer than 12 examined nodes, having stage T4
disease, or having perforation or obstruction. Multiple
high-risk factors included all other high-risk factor
combinations.
Table 2. Overall Survival and High-Risk Factors for Patients with Stage II Colon Cancer
Factor
Patients, No.
(events) HR (95% CI) P value
Patients with single high-risk factor (n = 318)
Age <50 y only 62 (3) 1 [Reference] NA
<12 Nodes examined 100 (17) 3.64 (1.07-12.43) .04
Perforation or obstruction 38 (6) 3.15 (0.79-12.60) .10
Stage T4 disease 67 (11) 3.39 (0.95-12.16) .06
Vascular or perineural invasion only 51 (4) 1.49 (0.33-6.66) .60
All patients (N = 573)
Favorable high-risk factorsa 132 (9) 1 [Reference] NA
Single unfavorable high-risk factorsb 297 (46) 2.40 (1.18-4.91) .02
Multiple high-risk factorsc 143 (29) 3.43 (1.62-7.25) .001
Abbreviations: HR, hazard ratio; NA, not applicable.
a Favorable high-risk factors were being younger than
50 years and/or having vascular or perineural
invasion.
b Single unfavorable high-risk factors were having
fewer than 12 nodes examined, having perforation or
obstruction, or having tumor stage 4.
c This category included all combinations of high-risk
factors combination.
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group. A Will Rogers20 stage migration phenomenon is likely, given that these results contrast with
the 3-year DFS rates of 81.3% achieved in the fluoropyrimidine-alone group and 86.3% in the same
FOLFOX4 regimen observed in patients with high-risk stage II CC in the MOSAIC trial.4 In the
complete stage II CC population, including high-risk and low-risk patients, the ACCENT analysis of 21
clinical trials with identical treatment (5-FU/LV–based therapy without oxaliplatin), survival rate was
better among patients treated from 1996 to 2007 compared with patients treated from 1978 to 1995
(89.0% vs 82.5%; HR, 0.67; 95% CI, 0.58-0.76). This reflects the stage migration over time,
challenging historical data related to the benefit of 5-FU/LV–based adjuvant therapy in such
patients.21 The 2.9% absolute improvement in OS demonstrated for stage II patients with adjuvant
chemotherapy in the QUASAR study might be substantially smaller if repeated in the current
clinical setting.
Our study does not suggest that bevacizumab may prolong DFS or OS of patients with high-risk
stage II CC even if the small number of patients and the lack of formal hypothesis in this exploratory
study must make us cautious. However, the effect of bevacizumab is not deleterious, as shown in
patients with stage III CC in the recent AVANT study update.19 The differential effect of bevacizumab
on survival between stage II and III could be partly explained by bevacizumab-induced tumor cell
dormancy phenomenon, which makes these cells inaccessible to chemotherapy.22,23 The lower risk
of having residual cells after the intervention in stage II CC than in stage III CC reduces the potential of
this negative effect of tumor dormancy. Besides, we cannot exclude a bevacizumab differential effect
according to primary tumor sidedness with a potential benefit in high-risk stage II right CC. This is in
accordance with the different prognosis between right and left CC in all settings, which is driven by
tumor biology.
The adverse effects remained moderate. The most serious adverse effects associated with
bevacizumab (ie, intestinal perforation and arterial thromboses) were not increased compared with
the control group.15 The younger age of the study population as well as their generally good health
could explain this observation.
Of note, statistically nonsignificant but numerically higher OS rates were observed in the XELOX
with bevacizumab group than in either FOLFOX4 group. A potential superiority of XELOX over
FOLFOX has been suggested among patients with low-risk stage III CC from the IDEA
meta-analysis.24 However, in the IDEA study, patients were not randomized between XELOX and
FOLFOX but between 3-month and 6-month durations of chemotherapy.
Limitations
This study has limitations, particularly the debatable definition of high-risk stage II CC. In this study,
the high-risk criteria were being younger than 50 years; having a local, stage T4 tumor; having
vascular or perineural invasion; having perforation or bowel obstruction; and having fewer than 12
lymph nodes examined. However, among our patients, being younger than 50 years had a good
prognosis, and neither vascular nor perineural tumoral invasion conferred negative outcomes. To be
more consistent with recent staging, it would have been also judicious to distinguish between tumors
with grade T4a and T4b and to separate obstruction from perforation.25
Furthermore, the very high prognostic value of circulating tumor DNA (ctDNA) for OS and
recurrence-free survival shown in small cohorts led to the development of larger studies to confirm
this prognostic value in stage II and III CC.26-28 The ultimate goal of these studies is to explore the
interest of ctDNA-driven adjuvant treatment.29
Conclusions
In this secondary analysis of data from the AVANT trial, bevacizumab did not improve DFS and OS in
the adjuvant setting among patients with high-risk stage II CC, but a potential benefit cannot be
excluded in patients with right-sided tumors. A better classification of stage II risk factors, including
ctDNA, will be useful for future studies, even if it is worth validating in ongoing studies.
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